Please login to the form below

Not currently logged in
Email:
Password:

nabiximols

This page shows the latest nabiximols news and features for those working in and with pharma, biotech and healthcare.

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance

The National Institute for Health and Care Excellence (NICE) did not recommend the use of GWPharma's Sativex (nabiximols), which is derived from the cannabis plant, or Biogen Idec's Fampyra

Latest news

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent

  • Glioblastomas - a personalised future? Glioblastomas - a personalised future?

    Also of note, the buccal spray nabiximols - an analgesic combination of delta-9-tetrahydrocannabinol and cannabidiol marketed for treatment of cancer and neuropathic pain and muscle spasticity, and the first cannabinoid ... Nabiximols inhibits glioma

  • Almirall expands in US via $400m deal to buy Aqua Almirall expands in US via $400m deal to buy Aqua

    under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    Sativex (nabiximols) is licensed to treat moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity medication and will be reimbursed by the Italian authorities

  • GW Pharma says German Sativex pricing GW Pharma says German Sativex pricing "unacceptable"

    Sativex (nabiximols) is an oromucosal spray containing active ingredients from the cannabis sativa plant used to treat moderate to severe spasticity in multiple sclerosis patients who have not responded to other

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics